EVQLV
New York
About EVQLV
EVQLV leverages advances in computation to revolutionize the design and development of antibody-based therapeutics, diagnostics, and reagents. EVQLV provides AI-powered de novo antibody discovery and antibody engineering to large molecule discovery scientists at biotechs, pharmaceutical companies, reagent distributors, and universities. EVQLV strives everyday to ensure that antibodies (including VHHs, ADCs, and BsAbs) can be developed faster, cheaper, and against hard targets.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $60.0K
- Funding stage: Seed
- Last round: Non-Equity Assistance (Aug 2023)
- Website: evqlv.com
- Phone: [email protected]
Industries & Categories
Artificial Intelligence (AI), Biotechnology, Life Science, Machine Learning, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/evqlv-56666 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.